Jeremie Menager
Overview
Explore the profile of Jeremie Menager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Menager J, Gorin J, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, et al.
Med Sci (Paris)
. 2016 May;
32(4):362-9.
PMID: 27137693
Alpha-radioimmunotherapy (α-RIT) is a targeted anti-tumor therapy using usually a monoclonal antibody specific for a tumor antigen that is coupled to an α-particle emitter. α-emitters represent an ideal tool to...
2.
Gorin J, Gouard S, Menager J, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, et al.
Front Med (Lausanne)
. 2015 Nov;
2:74.
PMID: 26539436
Objectives: Radiation emitted by the radionuclides in radioimmunotherapy (RIT) approaches induce direct killing of the targeted cells as well as indirect killing through the bystander effect. Our research group is...
3.
Menager J, Gorin J, Maurel C, Drujont L, Gouard S, Louvet C, et al.
PLoS One
. 2015 Jun;
10(6):e0130249.
PMID: 26098691
Ionizing radiation induces direct and indirect killing of cancer cells and for long has been considered as immunosuppressive. However, this concept has evolved over the past few years with the...
4.
Gorin J, Menager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, et al.
Neoplasia
. 2014 May;
16(4):319-28.
PMID: 24862758
Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for...
5.
Menager J, Ebstein F, Oger R, Hulin P, Nedellec S, Duverger E, et al.
PLoS One
. 2014 Mar;
9(2):e89897.
PMID: 24587108
Antitumor vaccination using synthetic long peptides (SLP) is an additional therapeutic strategy currently under development. It aims to activate tumor-specific CD8(+) CTL by professional APCs such as DCs. DCs can...
6.
Guillerme J, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, et al.
Clin Cancer Res
. 2013 Jan;
19(5):1147-58.
PMID: 23339127
Purpose: Plasmacytoid dendritic cells (pDC) are antigen-presenting cells specialized in antiviral response. The measles virus vaccine is proposed as an antitumor agent to target and specifically kill tumor cells without...